The Shocking Truth About Cognitive Health: Are You Ignoring These 7 Hidden Risks?

As the world of dementia research undergoes a significant shift, the picturesque Alpine town of Davos has become a focal point for a transformative approach. In January 2026, during the annual World Economic Forum, experts and advocates gathered to discuss a groundbreaking initiative—one that recognizes dementia not just as a health issue confined to wealthy nations but as a global equity challenge that requires urgent attention and innovation.

For years, Alzheimer’s disease and related disorders have been treated primarily through the lens of affluent countries. However, recent discussions emphasize that the most viable solutions may emerge from low- and middle-income regions that will face the largest future burdens of this disease. The Davos Alzheimer’s Collaborative (DAC) is spearheading this shift, aiming to embed diversity as a core principle in dementia research.

New Initiatives Across the Global South

At the heart of DAC's strategy is a commitment to enhancing research in countries such as Kenya, Chile, and Egypt. Drew Holzapfel, DAC Chief Operating Officer, outlined their vision: “We’re going into Kenya, Chile, Egypt… to better understand the heterogeneity of the disease.” The initiative focuses on testing new diagnostics, leveraging artificial intelligence (AI), and creating large-scale data platforms that can connect research communities globally.

Holzapfel highlighted key elements of this collaborative model:

• Expanding diverse data collection: This includes collecting data from populations previously underrepresented in research.
• Breaking down data silos: Creating platforms that allow researchers to share and analyze brain health data.
• Developing AI-driven discovery platforms: Integrating different data types to uncover causal mechanisms and personalized prevention strategies.
• Driving personalized treatments: An AI platform that could map causal mechanisms to specific biomarkers and therapeutic strategies.

DAC's collaboration with the Gates-funded Alzheimer’s Disease Data Initiative (ADDI) and the African Population Cohorts Consortium (APCC) serves as a model for how the power of big data can be harnessed. This initiative aims to create a data-sharing platform for African researchers, allowing them to access and analyze brain health and dementia-related data, ultimately paving the way for more informed research.

George Vradenburg, DAC founder and chairman, pointed out a pressing reality: “The Global South will have 80% of cases of dementia in the next 20 years.” This statistic underscores the urgency for researchers, policymakers, and investors to confront a crucial truth: innovation that overlooks the global majority is not only inequitable but also incomplete.

Understanding Diversity’s Role in Dementia Research

Traditionally, biomedical research on dementia has focused on data predominantly derived from populations of European ancestry, leading to an incomplete understanding of how the disease affects different demographics. “90% of the data in genome-wide association studies is built upon European ancestry… but only 10% of the world is of that ancestry,” Holzapfel noted, emphasizing the need for more diverse data to create effective interventions for everyone.

Incorporating diverse populations into dementia research offers a richer tapestry of genetic profiles, environmental exposures, and disease pathways. Michael Cook, Chief Science Officer at Our Future Health, stated, “Diversity will help ensure that we create medications and interventions that fit for all populations.”

Moreover, the Global South is seen as an area ripe for innovation, particularly concerning cost-effective solutions for diagnosing and treating dementia. The DAC is focused on non-invasive diagnostics that could reach communities where specialist care is lacking. This includes initiatives testing digital voice imprints and olfactory gland assessments as potential diagnostic tools.

Sam Barrell, CEO of LifeArc, emphasizes the need for new diagnostic methods, stating, “Most people do not have access to gold-standard diagnostics—such as PET scans and spinal fluid tests—which are costly and invasive.” LifeArc is co-sponsoring a project aimed at developing lower-cost alternatives, with initial results expected by 2028.

As Barrell explained, early predictive tests could transform dementia care. “If you can intervene earlier on those lifestyle factors that make you more likely to develop dementia, it would make a big difference in the long term,” he added.

The discussion on AI and its implications for dementia research is equally complex. While AI offers unprecedented reach and cost efficiencies, there are concerns about reinforcing existing inequities. Peter Lee, President of Microsoft Research, warned that current AI models are predominantly oriented toward the Global North, risking misdiagnosis or exclusion for populations in the Global South.

Nevertheless, Holzapfel noted promising developments in India, where DAC is establishing a branch to explore cognitive health through workplace studies and voice analysis. “If you fast forward, the real opportunity here is to have ambient voice collection in the doctor’s office that listens and determines if you have cognitive impairment,” he said.

The DAC’s Global Cohorts initiative is another step toward integrating diverse research efforts. By linking initiatives across regions—from Kenya to Malaysia and the Caribbean—DAC aims to reduce research costs and amplify results. This initiative involves testing new diagnostic tools that can be scaled effectively across varied healthcare contexts.

As the landscape of dementia research evolves, it’s clear that a collaborative, inclusive approach not only addresses equity concerns but also enhances the efficacy of research outcomes. By recognizing the Global South as a vital player in the search for dementia solutions, the DAC is paving the way for innovations that could benefit everyone, regardless of their geographic or economic circumstances.